[PD-1抑制剂联合纳布紫杉醇和顺铂在局部晚期下咽鳞癌新辅助治疗中的疗效】。]

Q4 Medicine
Q Fang, P F Xu, F Cao, Z Zhao, X R Zhang, D Wu, C Y Chen, Z M Li, F Han, X K Liu
{"title":"[PD-1抑制剂联合纳布紫杉醇和顺铂在局部晚期下咽鳞癌新辅助治疗中的疗效】。]","authors":"Q Fang, P F Xu, F Cao, Z Zhao, X R Zhang, D Wu, C Y Chen, Z M Li, F Han, X K Liu","doi":"10.3760/cma.j.cn115330-20231016-00152","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To assess the efficacy of neoadjuvant treatment with PD-1 (programmed cell death protein 1) inhibitors combined with paclitaxel (albumin-conjugated) and cisplatin (TP regimen) for locally advanced hypopharyngeal squamous cell carcinoma and laryngeal organ function preservation. <b>Methods:</b> Data of 53 patients, including 51 males and 2 females, aged 38-70 years old, who were diagnosed with locally advanced hypopharyngeal squamous carcinoma confirmed by histology and enhanced CT at the Cancer Prevention and Control Center of Sun Yat-sen University during the initial treatment from January 1, 2019 to January 15, 2023, were retrospectively analyzed. All patients received neoadjuvant therapy with PD-1 inhibitors combined with albumin-bound paclitaxel (260 mg/m<sup>2</sup>) and cisplatin (60 mg/m<sup>2</sup>) for 3 to 4 cycles. The main outcome measures were larynx dysfunction-free survival (LDFS), overall survival (OS), and progression-free survival (PFS). Survival curves were plotted using the Kaplan-Meier method, and Cox multifactorial analysis was further performed if Cox univariate analysis was statistically significant. <b>Results:</b> The overall efficiency was 90.6% (48/53). The 1-year and 2-year LDFS rates were 83.8% (95%<i>CI</i>: 74.0% to 94.8%) and 50.3% (95%<i>CI</i>: 22.1% to 91.6%), the 1-year and 2-year OS rates were 95.2% (95%<i>CI</i>: 88.9% to 100.0%) and 58.2% (95%<i>CI</i>: 25.6% to 81.8%), and the 1-year and 2-year PFS rates were 83.9% (95%<i>CI</i>: 74.2% to 94.9%) and 53.5% (95%<i>CI</i>: 32.1% to 89.1%). Adverse events associated with the neoadjuvant therapy were mainly myelosuppression (45.3%), gastrointestinal reactions (37.7%) and hypothyroidism (20.8%). <b>Conclusion:</b> The neoadjuvant treatment of locally advanced hypopharyngeal squamous cell carcinoma using PD-1 inhibitors combined with paclitaxel and cisplatin can provide with a higher survival rate with a improved laryngeal organ function preservation rate.</p>","PeriodicalId":23987,"journal":{"name":"Chinese journal of otorhinolaryngology head and neck surgery","volume":"59 7","pages":"750-757"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Efficacy of PD-1 inhibitors combined with nab-paclitaxel and cisplatin in the neoadjuvant treatment of locally advanced hypopharyngeal squamous cell carcinoma].\",\"authors\":\"Q Fang, P F Xu, F Cao, Z Zhao, X R Zhang, D Wu, C Y Chen, Z M Li, F Han, X K Liu\",\"doi\":\"10.3760/cma.j.cn115330-20231016-00152\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> To assess the efficacy of neoadjuvant treatment with PD-1 (programmed cell death protein 1) inhibitors combined with paclitaxel (albumin-conjugated) and cisplatin (TP regimen) for locally advanced hypopharyngeal squamous cell carcinoma and laryngeal organ function preservation. <b>Methods:</b> Data of 53 patients, including 51 males and 2 females, aged 38-70 years old, who were diagnosed with locally advanced hypopharyngeal squamous carcinoma confirmed by histology and enhanced CT at the Cancer Prevention and Control Center of Sun Yat-sen University during the initial treatment from January 1, 2019 to January 15, 2023, were retrospectively analyzed. All patients received neoadjuvant therapy with PD-1 inhibitors combined with albumin-bound paclitaxel (260 mg/m<sup>2</sup>) and cisplatin (60 mg/m<sup>2</sup>) for 3 to 4 cycles. The main outcome measures were larynx dysfunction-free survival (LDFS), overall survival (OS), and progression-free survival (PFS). Survival curves were plotted using the Kaplan-Meier method, and Cox multifactorial analysis was further performed if Cox univariate analysis was statistically significant. <b>Results:</b> The overall efficiency was 90.6% (48/53). The 1-year and 2-year LDFS rates were 83.8% (95%<i>CI</i>: 74.0% to 94.8%) and 50.3% (95%<i>CI</i>: 22.1% to 91.6%), the 1-year and 2-year OS rates were 95.2% (95%<i>CI</i>: 88.9% to 100.0%) and 58.2% (95%<i>CI</i>: 25.6% to 81.8%), and the 1-year and 2-year PFS rates were 83.9% (95%<i>CI</i>: 74.2% to 94.9%) and 53.5% (95%<i>CI</i>: 32.1% to 89.1%). Adverse events associated with the neoadjuvant therapy were mainly myelosuppression (45.3%), gastrointestinal reactions (37.7%) and hypothyroidism (20.8%). <b>Conclusion:</b> The neoadjuvant treatment of locally advanced hypopharyngeal squamous cell carcinoma using PD-1 inhibitors combined with paclitaxel and cisplatin can provide with a higher survival rate with a improved laryngeal organ function preservation rate.</p>\",\"PeriodicalId\":23987,\"journal\":{\"name\":\"Chinese journal of otorhinolaryngology head and neck surgery\",\"volume\":\"59 7\",\"pages\":\"750-757\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chinese journal of otorhinolaryngology head and neck surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/cma.j.cn115330-20231016-00152\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese journal of otorhinolaryngology head and neck surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn115330-20231016-00152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的评估PD-1(程序性细胞死亡蛋白1)抑制剂联合紫杉醇(白蛋白结合型)和顺铂(TP方案)新辅助治疗局部晚期下咽鳞状细胞癌的疗效以及喉部器官功能的保留情况。治疗方法回顾性分析2019年1月1日至2023年1月15日期间中山大学肿瘤防治中心初治的53例经组织学和增强CT确诊为局部晚期下咽鳞癌的患者数据,其中男51例,女2例,年龄38-70岁。所有患者均接受了PD-1抑制剂联合白蛋白结合型紫杉醇(260毫克/平方米)和顺铂(60毫克/平方米)的新辅助治疗,共3至4个周期。主要结果指标为无喉功能障碍生存期(LDFS)、总生存期(OS)和无进展生存期(PFS)。采用Kaplan-Meier法绘制生存曲线,如果Cox单变量分析具有统计学意义,则进一步进行Cox多因素分析。结果总有效率为90.6%(48/53)。1年和2年LDFS率分别为83.8%(95%CI:74.0%至94.8%)和50.3%(95%CI:22.1%至91.6%),1年和2年OS率分别为95.2%(95%CI:88.9%至100.0%)和58.2%(95%CI:25.6%至81.8%),1年和2年PFS率分别为83.9%(95%CI:74.2%至94.9%)和53.5%(95%CI:32.1%至89.1%)。与新辅助治疗相关的不良反应主要是骨髓抑制(45.3%)、胃肠道反应(37.7%)和甲状腺功能减退(20.8%)。结论使用PD-1抑制剂联合紫杉醇和顺铂对局部晚期下咽鳞癌进行新辅助治疗可提高生存率,并改善喉部器官功能的保留率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Efficacy of PD-1 inhibitors combined with nab-paclitaxel and cisplatin in the neoadjuvant treatment of locally advanced hypopharyngeal squamous cell carcinoma].

Objective: To assess the efficacy of neoadjuvant treatment with PD-1 (programmed cell death protein 1) inhibitors combined with paclitaxel (albumin-conjugated) and cisplatin (TP regimen) for locally advanced hypopharyngeal squamous cell carcinoma and laryngeal organ function preservation. Methods: Data of 53 patients, including 51 males and 2 females, aged 38-70 years old, who were diagnosed with locally advanced hypopharyngeal squamous carcinoma confirmed by histology and enhanced CT at the Cancer Prevention and Control Center of Sun Yat-sen University during the initial treatment from January 1, 2019 to January 15, 2023, were retrospectively analyzed. All patients received neoadjuvant therapy with PD-1 inhibitors combined with albumin-bound paclitaxel (260 mg/m2) and cisplatin (60 mg/m2) for 3 to 4 cycles. The main outcome measures were larynx dysfunction-free survival (LDFS), overall survival (OS), and progression-free survival (PFS). Survival curves were plotted using the Kaplan-Meier method, and Cox multifactorial analysis was further performed if Cox univariate analysis was statistically significant. Results: The overall efficiency was 90.6% (48/53). The 1-year and 2-year LDFS rates were 83.8% (95%CI: 74.0% to 94.8%) and 50.3% (95%CI: 22.1% to 91.6%), the 1-year and 2-year OS rates were 95.2% (95%CI: 88.9% to 100.0%) and 58.2% (95%CI: 25.6% to 81.8%), and the 1-year and 2-year PFS rates were 83.9% (95%CI: 74.2% to 94.9%) and 53.5% (95%CI: 32.1% to 89.1%). Adverse events associated with the neoadjuvant therapy were mainly myelosuppression (45.3%), gastrointestinal reactions (37.7%) and hypothyroidism (20.8%). Conclusion: The neoadjuvant treatment of locally advanced hypopharyngeal squamous cell carcinoma using PD-1 inhibitors combined with paclitaxel and cisplatin can provide with a higher survival rate with a improved laryngeal organ function preservation rate.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
12432
期刊介绍: Chinese journal of otorhinolaryngology head and neck surgery is a high-level medical science and technology journal sponsored and published directly by the Chinese Medical Association, reflecting the significant research progress in the field of otorhinolaryngology head and neck surgery in China, and striving to promote the domestic and international academic exchanges for the purpose of running the journal. Over the years, the journal has been ranked first in the total citation frequency list of national scientific and technical journals published by the Documentation and Intelligence Center of the Chinese Academy of Sciences and the China Science Citation Database, and has always ranked first among the scientific and technical journals in the related fields. Chinese journal of otorhinolaryngology head and neck surgery has been included in the authoritative databases PubMed, Chinese core journals, CSCD.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信